Chapter 567 Hyperparathyroidism
Differential Diagnosis
Other causes of hypercalcemia can result in a similar clinical pattern and must be differentiated from hyperparathyroidism (Table 567-1). A low serum phosphorus level with hypercalcemia is characteristic of primary hyperparathyroidism; elevated levels of PTH are also diagnostic. With hypercalcemia of any cause except hyperparathyroidism and familial hypocalciuric hypercalcemia, PTH levels are suppressed. Pharmacologic doses of corticosteroids lower the serum calcium level to normal in patients with hypercalcemia from other causes but generally do not affect the calcium level in patients with hyperparathyroidism.
Table 567-1 ETIOLOGIC CLASSIFICATION OF HYPERCALCEMIA
PARATHYROID HORMONE EXCESS (PRIMARY HYPERPARATHYROIDISM)
PARATHYROID HORMONE-RELATED PEPTIDE EXCESS
Ca2+-SENSING RECEPTOR INACTIVATING MUTATION
ACTIVATING MUTATION OF PTH/PTHrP RECEPTOR
INACTIVATING MUTATION OF PTH/PTHrP RECEPTOR
VITAMIN D EXCESS
UNKNOWN CAUSE
Williams syndrome (7q11.23 deletion)
OTHER
PTH, parathyroid hormone; PTHrP, parathyroid hormone-related peptide.
567.1 Other Causes of Hypercalcemia
Miscellaneous Causes of Hypercalcemia
Hypophosphatasia, especially the severe infantile form, is usually associated with mild to moderate hypercalcemia (Chapter 696). Serum levels of phosphorus are normal, and those of alkaline phosphatase are subnormal. The bones exhibit rachitic-like lesions on radiographs. Urinary levels of phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5′-phosphate are elevated; each is a natural substrate to a tissue-nonspecific (liver, bone, kidney) alkaline phosphatase enzyme. Missense mutations of the tissue-nonspecific alkaline phosphatase enzyme gene result in an inactive enzyme in this autosomal recessive disorder.
Jansen-type metaphyseal chondrodysplasia is a rare genetic disorder characterized by short-limbed dwarfism and severe but asymptomatic hypercalcemia (Chapter 695). Circulating levels of PTH and PTHrP are undetectable. These patients have an activating PTH-PTHrP receptor mutation that results in aberrant calcium homeostasis and abnormalities of the growth plate.
Alos N, Eugene D, Fillion M, et al. Pamidronate: treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. Horm Res. 2006;65(6):289-294.
Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome. Nat Genet. 2002;32(4):676-680.
Domico MB, Huynh V, Anand SK, et al. Severe hyperphosphatemia and hypocalcemic tetany after oral laxative administration in a 3-month-old infant. Pediatrics. 2006;118(5):e1580-e1583.
Ewart AK, Morris CA, Atkinson D, et al. Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet. 1993;5:11-16.
Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145-156.
Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics. 2005;115:974-980.
Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863-1875.
Obermannova B, Banghova K, Sumnik Z, et al. Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur J Pediatr. 2009;168(5):569-573.
Pearce SH, Williamson C, Thaker RV, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med. 1996;335:1115-1122.
Schipani E, Langman CB, Juppner H, et al. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen’s metaphyseal chondrodysplasia. N Engl J Med. 1996;335:708-714.
Shalev H, Phillip M, Landau D, et al. Clinical presentation and outcome in primary familial hypomagnesaemia. Arch Dis Child. 1998;78:127-130.
Sitges-Serra A, Bergenfelz A. Clinical update: sporadic primary hyperparathyroidism. Lancet. 2007;370:468-470.